Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.

Front Oncol · 2020 · PMC7033582 · PMID 32117745

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although a previous meta-analysis showed a trend of a high incidence of elevated levels of ALT and AST in melanoma patients treated with nivolumab versus pembrolizumab ( 69 ), our analyses revealed a higher incidence of these potential irAEs in patients treated with pembrolizumab.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.